Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms Clinical Trial

Official title:

Crizotinib (Xalkori (Registered)) Expanded Access Protocol For The Treatment Of Japanese Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Ros1 Oncogene

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT02824094
• Other study ID #: A8081064
• Status: No longer available
• Phase: N/A
• First received: June 30, 2016
• Last updated: July 18, 2017

Study information

• Verified date: July 2017
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic.

• Positive for translocation or inversion events involving the ROS1 gene as determined by protocol defined test.

• ECOG performance status 0 to 2.

• Adequate organ function

• Patients with brain metastases are eligible if neurologically stable for at least 2 weeks and have no ongoing requirement for corticosteroids.

• Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of crizotinib.

Exclusion Criteria:

• Currently receiving crizotinib or any investigational products.

• Prior therapy specifically directed against ROS1 fusion genes including crizotinib.

• Carcinomatous meningitis or leptomeningeal disease.

• Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function.

• Ongoing uncontrolled congestive heart failure (CHF) and any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack.

• Ongoing cardiac dysrhythmias of CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QTc more than 480 msec.

• History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.

• Pregnant female patients; breastfeeding female patients.

• Use of drugs or foods including known potent CYP3A4 inhibitors, known potent CYP3A4 inducers and CYP3A4 substrates with narrow therapeutic indices

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Neoplasms

Intervention

Drug:
• crizotinib
Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule

Locations

Country	Name	City	State
Japan	Hyogo Cancer Center	Akashi	Hyogo
Japan	National Cancer Center Hospital East	Kashiwa	Chiba
Japan	The Cancer Institute Hospital of JFCR	Koto-ku, Tokyo
Japan	Aichi cancer center central hospital	Nagoya	Aichi

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Japan, 

External Links

•   To obtain contact information for a study center near you, click here.